The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -99,961 |
| Reduction in the carrying amount of rou assets, operating | 1,491 |
| Reduction in the carrying amount of rou assets, finance | 320 |
| Stock based compensation expense | 12,132 |
| Depreciation and amortization expense | 268 |
| Non-cash gain on long-term investment | 3,390 |
| Net realized gain on investments in u.s. treasury securities | 17 |
| Amortization of premium (accretion of discount) on investments in u.s. treasury securities | -111 |
| Prepaid expenses and other current assets | 2,004 |
| Accounts payable | -1,561 |
| Accrued expenses and other current liabilities | -4,445 |
| Lease liabilities, operating | -1,496 |
| Lease liabilities, finance | -9 |
| Net cash used in operating activities | -98,561 |
| Purchase of property and equipment | 397 |
| Purchases of investments | 195,382 |
| Proceeds from sales or maturities of investments | 105,527 |
| Net cash used in investing activities | -90,252 |
| Proceeds from exercise of stock options | 59 |
| Payments on finance leases | 533 |
| Proceeds from common stock issuances under 2023 espp | 270 |
| Proceeds from issuance of common stock, pre-funded warrants and warrants to purchase common stock upon may 2025 private placement | 79,999 |
| Payment of financing and stock issuance costs | 6,917 |
| Proceeds from issuance of common stock and pre-funded warrants to purchase common stock upon october 2025 financing transactions | 153,750 |
| Third-party commissions and offering costs incurred upon october 2025 financing transactions | 9,833 |
| Net cash provided by financing activities | 216,795 |
| Net change in cash, cash equivalents and restricted cash | 27,982 |
| Cash, cash equivalents and restricted cash at beginning of period | 38,266 |
| Cash, cash equivalents and restricted cash at end of period | 66,248 |
Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics, Inc. (LXEO)